Beyond Air - יחס שווי חברה להכנסות XAIR

Beyond Air, Inc. (XAIR) is developing the innovative LungFit system to combat pulmonary infections, maintaining its leadership through massive R&D expenditures. The technology for synthesizing therapeutic gas from air eliminates the need for cylinders, streamlining clinic logistics. Commercial sales expansion and rising demand for consumables are optimizing costs. The EV/Sales ratio demonstrates a fundamental trend, with the current level sitting around 1334.55.
XAIR (beyondair.net): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The market evaluates the potential of Beyond Air, Inc. (XAIR) through the lens of the LungFit system's expansion, where the EV/Sales multiple reflects the enterprise value relative to generated revenue. By analyzing the EV/Sales history, an investor may uncover hidden risks within the price consolidation, which, for this B2B model, signals a possible asset revaluation prior to a phase of volatility.